Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Minimal Residual Disease (MRD) Status Predicts Outcomes in Patients with Follicular Lymphoma (FL) Treated with Chemo-Immunotherapy on SWOG S0016

Alexey Danilov, Hongli Li, Mazyar Shadman, Lisa M. Rimsza, Ahmad Zebari, Sonali M. Smith, Michael Leblanc, Jonathan W. Friedberg, Christopher Carlson, Joo Y Song

Blood (2023) 142 (Supplement 1): 4359.

https://doi.org/10.1182/blood-2023-179612

Published: 2023

Journal Articles

Progression-Free Survival (PFS) and Toxicity with Nivolumab-AVD Compared to Brentuximab Vedotin-AVD in Pediatric Advanced Stage (AS) Classic Hodgkin Lymphoma (cHL), Results of SWOG S1826

Blood (2023) 142 (Supplement 1): 610.

https://doi.org/10.1182/blood-2023-180107

Published: 2023

Journal Articles

Nivolumab-AVD Is Better Tolerated and Improves Progression-Free Survival Compared to Bv-AVD in Older Patients (Aged ≥60 Years) with Advanced Stage Hodgkin Lymphoma Enrolled on SWOG S1826

Blood (2023) 142 (Supplement 1): 181.

https://doi.org/10.1182/blood-2023-180114

Published: 2023

Journal Articles

Trial-in-Progress: Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma (NCT#03269669): SWOG S1608

Paul M. Barr, Hongli Li, Brian K. Link, Christopher R. Flowers, Richard Burack, Heiko Schöder, Michael L. Leblanc, Oliver Weigert, Alex F. Herrera, David M. Weinstock, John P. Leonard, Brad S. Kahl, Sonali M. Smith, Jonathan W. Friedberg

Blood (2021) 138 (Supplement 1): 2425.

https://doi.org/10.1182/blood-2021-146182

Published: 2021

Journal Articles

Extranodal Presentation in Limited Stage DLBCL As a Prognostic Marker in Three Sequential SWOG Trials S0014, S0313 and S1001 (NCT00005089, NCT00070018, NCT01359592)

Deborah M. Stephens, Hongli Li, Louis S. Constine, John P. Leonard, Brad S. Kahl, Joo Y Song, Michael L. Leblanc, Thomas J. Fitzgerald, Sonali M. Smith, Jonathan W. Friedberg, Dan O. Persky

Blood (2021) 138 (Supplement 1): 1423.

https://doi.org/10.1182/blood-2021-147938

Published: 2021

Journal Articles

S1918: A Phase II/III Randomized Study of R-Minichop with or without Oral Azacitidine (CC-486) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIb Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements

Elizabeth A Brem, Hongli Li, Anne W. Beaven, Paolo F. Caimi, Leandro Cerchietti, Ash A. Alizadeh, Rebecca L. Olin, Norah Lynn Henry, Hildy Dilon, Richard F. Little, Cara Laubach, Michael L. Leblanc, Jonathan W. Friedberg, Sonali M. Smith

Blood (2021) 138 (Supplement 1): 3565.

https://doi.org/10.1182/blood-2021-148193

Published: 2021

Journal Articles

Evaluation of Activation of a NCI National Clinical Trials Network (NCTN) Study S1826 for Hodgkin Lymphoma (HL) at Children's Oncology Group (COG) Institutions

Sharon M. Castellino, MD MSc, Angela Punnett, MD, Susan K Parsons, MD MRP, Nicholas P. DeGroote, MPH, Sally Muehle, Hongli Li, MS, Michael E. Roth, MD, Alex F. Herrera, MD, Jonathan W. Friedberg, MD MSSc, Nita L. Seibel, MD, Kara M. Kelly, MD

Blood (2020) 136 (Supplement 1): 20.

https://doi.org/10.1182/blood-2020-134738

Published: 2020

Journal Articles

SWOG S1826: A Phase III, Randomized Study of Nivolumab Plus AVD or Brentuximab Vedotin Plus AVD in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-136422

Published: 2020

Journal Articles

PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of Intergroup Nctn Study S1001

Daniel O. Persky, MD, Hongli Li, MS, Deborah M. Stephens, DO, Steven I Park, MD, Nancy L. Bartlett, MD, Lode J. Swinnen, MB ChB, Paul M. Barr, MD, Jerome D. Winegarden, III, MD, Louis S. Constine, MD, Thomas J. Fitzgerald, MD, John P. Leonard, MD, Brad S. Kahl, MD, Michael L. Leblanc, PhD, Joo Y. Song, MD, Richard I. Fisher, MD, Lisa M. Rimsza, MD, Sonali M. Smith, MD, Jonathan W. Friedberg, MD

Blood (2019) 134 (Supplement_1): 349.

https://doi.org/10.1182/blood-2019-123871

Published: 2019

Journal Articles

Intraclonal Heterogeneity Caused By Activation-Induced Cytidine Deaminase Is Not a Prognostic Biomarker in Untreated Advanced Stage Follicular Lymphoma: An Analysis of SWOG S0016

Richard Burack, MD PhD, Hongli Li, MS, Diana G Adlowitz, PhD, Janice M Spence, PhD, Michael L. Leblanc, PhD, Lisa M. Rimsza, MD, Rita M. Braziel, MD, Catherine M. Spier, MD, Mark S Kaminski, MD, John P. Leonard, MD, Richard I. Fisher, MD, Sonali M. Smith, MD, Jonathan W. Friedberg, MD

Blood (2019) 134 (Supplement_1): 2771.

https://doi.org/10.1182/blood-2019-121632

Published: 2019

Journal Articles

Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma

Deborah M. Stephens, Hongli Li, Heiko Schöder, David J. Straus, Craig H. Moskowitz, Michael LeBlanc, Lisa M. Rimsza, Nancy L. Bartlett, Andrew M. Evens, Ann S. LaCasce, Paul M. Barr, Michael V. Knopp, Eric D. Hsi, John P. Leonard, Brad S. Kahl, Sonali M. Smith, Jonathan W. Friedberg

Blood (2019) 134 (15): 1238–1246.

https://doi.org/10.1182/blood.2019000719

Published: 2019

Includes: Supplemental data

Journal Articles

Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study

Eric D. Hsi, Hongli Li, Andrew B. Nixon, Heiko Schöder, Nancy L. Bartlett, Michael LeBlanc, Sonali Smith, Brad S. Kahl, John P. Leonard, Andrew M. Evens, David W. Scott, Lisa M. Rimsza, Jonathan W. Friedberg

Blood (2019) 133 (16): 1762–1765.

https://doi.org/10.1182/blood-2018-08-870915

Published: 2019

Includes: Supplemental data

Journal Articles

Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016

Xiaoyu Qu, Hongli Li, Rita M. Braziel, Verena Passerini, Lisa M. Rimsza, Eric D. Hsi, John P. Leonard, Sonali M. Smith, Robert Kridel, Oliver Press, Oliver Weigert, Michael LeBlanc, Jonathan W. Friedberg, Min Fang

Blood (2019) 133 (1): 81–93.

https://doi.org/10.1182/blood-2018-07-865428

Published: 2019

Includes: Supplemental data

Journal Articles

Subclonal Mutations of TP53 Are Common in Untreated Follicular Lymphoma and Mutation Status Is Predictive of PFS When CHOP Is Combined with 131-Iodine Tositumomab but Not with Rituximab: An Analysis of SWOG S0016

Richard Burack, MD PhD, Hongli Li, MS, Janice M Spence, PhD, Diana Adlowitz, Lisa M. Rimsza, MD, Rita M. Braziel, MD, Catherine M. Spier, MD, Mark S Kaminski, MD, John P. Leonard, MD, Richard I. Fisher, MD, Michael L. Leblanc, PhD, Sonali M. Smith, MD, Jonathan W. Friedberg, MD

Blood (2018) 132 (Supplement 1): 919.

https://doi.org/10.1182/blood-2018-99-111399

Published: 2018

Journal Articles

Long-Term Follow-up of SWOG S0816: Response-Adapted Therapy for Stage III/IV Hodgkin Lymphoma Demonstrates Limitations of PET-Adapted Approach

Deborah M. Stephens, Hongli Li, MS, Heiko Schoder, MD, David J. Straus, MD, Craig H. Moskowitz, MD, Michael L. Leblanc, PhD, Lisa M. Rimsza, MD, Nancy L. Bartlett, MD, Andrew M. Evens, DO, MSc, Ann S. LaCasce, MD MSc, Paul Barr, MD, Michael V. Knopp, Eric D. Hsi, MD, John P. Leonard, MD, Brad S Kahl, MD, Sonali M. Smith, MD, Jonathan W. Friedberg, MD

Blood (2018) 132 (Supplement 1): 929.

https://doi.org/10.1182/blood-2018-99-113034

Published: 2018

Journal Articles

Potential Impact of Consolidation Radiation Therapy for Advanced Hodgkin Lymphoma: A Secondary Modeling of SWOG S0816 with Receiver Operating Characteristic Analysis

Chul S. Ha, MD, Hongli Li, MS, Heiko Schoder, MD, Chelsea C Pinnix, MD, Elizabeth Brem, MD, Nancy L. Bartlett, MD, Andrew M. Evens, DO, MSc, Eric D. Hsi, MD, Lisa M. Rimsza, MD, John P. Leonard, MD, Brad S Kahl, MD, Michael L. Leblanc, PhD, Sonali M. Smith, MD, Louis S. Constine, MD, Jonathan W. Friedberg, MD

Blood (2018) 132 (Supplement 1): 2927.

https://doi.org/10.1182/blood-2018-99-113133

Published: 2018

Journal Articles

Five-Year Outcomes of SWOG S1106: A Randomized Phase II US Intergroup Study of R-HCVAD Vs. R-Bendamustine Followed By Autologous Stem Cell Transplant for Patients with Mantle Cell Lymphoma

Manali Kamdar, MD, Hongli Li, MS, Robert W. Chen, MD, Lisa M. Rimsza, MD, Michael L. Leblanc, PhD, Timothy S. Fenske, MD, Paul Barr, MD, Tycel J. Phillips, MD, John P. Leonard, MD, Brad S Kahl, MD, Jonathan W. Friedberg, MD, Sonali M. Smith, MD

Blood (2018) 132 (Supplement 1): 1593.

https://doi.org/10.1182/blood-2018-99-112752

Published: 2018

Journal Articles

Prognostic Utility of Serum TARC, MDC, IL10, and Soluble CD163 Levels with Positron Emission Tomography (PET) Response-Adapted Therapy for Advanced-Stage Hodgkin Lymphoma (HL): a SWOG S0816 US Intergroup Correlative Study

Eric D. Hsi, MD, Hongli Li, MS, Andrew B. Nixon, PhD, Andrew M Evens, DO,MSc, Heiko Schoder, MD, David J. Straus, MD, Nancy L. Bartlett, MD, John William Sweetenham, MDFRCP, Paul M. Barr, MD, Michelle A. Fanale, MD, James R. Cook, MD PhD, Brad S Kahl, MD, John P. Leonard, MD, Sonali M. Smith, MD, Michael L. Leblanc, PhD, Lisa M. Rimsza, MD, Jonathan W. Friedberg, MD, Oliver W. Press, MD PhD

Blood (2017) 130 (Supplement 1): 4033.

https://doi.org/10.1182/blood.V130.Suppl_1.4033.4033

Published: 2017

Journal Articles

Characteristics and Outcomes of Patients with Double-Protein Expression in Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of SWOG Study S1001 (NCT01359592)

Deborah M. Stephens, DO, Hongli Li, MS, Daniel Persky, MD, Steven I. Park, MD, Nancy L. Bartlett, MD, Lode J. Swinnen, Carla Casulo, MD, Jerome D. Winegarden, III, MD, Louis S. Constine, MD, Thomas J. Fitzgerald, MD, John P. Leonard, MD, Brad S Kahl, MD, Michael L. Leblanc, PhD, Joo Y. Song, MD, Richard I. Fisher, MD, Lisa M. Rimsza, MD, Sonali M. Smith, MD, Jonathan W. Friedberg, MD

Blood (2017) 130 (Supplement 1): 4122.

https://doi.org/10.1182/blood.V130.Suppl_1.4122.4122

Published: 2017

Journal Articles

Genomic Alterations Important for the Prognosis in Patients with Follicular Lymphoma Treated on SWOG Study S0016

Xiaoyu Qu, PhD, Hongli Li, MS, Oliver W. Press, MD PhD, Lisa M. Rimsza, MD, Rita M. Braziel, MD, Michael L. Leblanc, PhD, Eric D. Hsi, MD, John P. Leonard, MD, Sonali M. Smith, MD, Jonathan W. Friedberg, MD, Min Fang, MDPhD

Blood (2017) 130 (Supplement 1): 1507.

https://doi.org/10.1182/blood.V130.Suppl_1.1507.1507

Published: 2017

NARROW

Minimal Residual Disease (MRD) Status Predicts Outcomes in Patients with Follicular Lymphoma (FL) Treated with Chemo-Immunotherapy on SWOG S0016

Progression-Free Survival (PFS) and Toxicity with Nivolumab-AVD Compared to Brentuximab Vedotin-AVD in Pediatric Advanced Stage (AS) Classic Hodgkin Lymphoma (cHL), Results of SWOG S1826

Nivolumab-AVD Is Better Tolerated and Improves Progression-Free Survival Compared to Bv-AVD in Older Patients (Aged ≥60 Years) with Advanced Stage Hodgkin Lymphoma Enrolled on SWOG S1826

Trial-in-Progress: Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma (NCT#03269669): SWOG S1608

Extranodal Presentation in Limited Stage DLBCL As a Prognostic Marker in Three Sequential SWOG Trials S0014, S0313 and S1001 (NCT00005089, NCT00070018, NCT01359592)

Evaluation of Activation of a NCI National Clinical Trials Network (NCTN) Study S1826 for Hodgkin Lymphoma (HL) at Children's Oncology Group (COG) Institutions

SWOG S1826: A Phase III, Randomized Study of Nivolumab Plus AVD or Brentuximab Vedotin Plus AVD in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of Intergroup Nctn Study S1001

Intraclonal Heterogeneity Caused By Activation-Induced Cytidine Deaminase Is Not a Prognostic Biomarker in Untreated Advanced Stage Follicular Lymphoma: An Analysis of SWOG S0016

Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma

Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study

Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016

Subclonal Mutations of TP53 Are Common in Untreated Follicular Lymphoma and Mutation Status Is Predictive of PFS When CHOP Is Combined with 131-Iodine Tositumomab but Not with Rituximab: An Analysis of SWOG S0016

Long-Term Follow-up of SWOG S0816: Response-Adapted Therapy for Stage III/IV Hodgkin Lymphoma Demonstrates Limitations of PET-Adapted Approach

Potential Impact of Consolidation Radiation Therapy for Advanced Hodgkin Lymphoma: A Secondary Modeling of SWOG S0816 with Receiver Operating Characteristic Analysis

Five-Year Outcomes of SWOG S1106: A Randomized Phase II US Intergroup Study of R-HCVAD Vs. R-Bendamustine Followed By Autologous Stem Cell Transplant for Patients with Mantle Cell Lymphoma

Prognostic Utility of Serum TARC, MDC, IL10, and Soluble CD163 Levels with Positron Emission Tomography (PET) Response-Adapted Therapy for Advanced-Stage Hodgkin Lymphoma (HL): a SWOG S0816 US Intergroup Correlative Study

Characteristics and Outcomes of Patients with Double-Protein Expression in Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of SWOG Study S1001 (NCT01359592)

Genomic Alterations Important for the Prognosis in Patients with Follicular Lymphoma Treated on SWOG Study S0016

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only